Pick any major technology that could shape the future, and there's a good chance Alphabet is already a leader in it.
Buying Amazon shares on pullbacks has always paid off handsomely over the long run.
BeOne Medicines ranks as one of the most promising biotech stocks on the market.
Investors have lots of pithy adages. One of my favorites is: "Time in the market beats timing the market." The quote is often attributed to billionaire investor Ken Fisher. And it's spot on.
Of course, which stocks you own during your time in the market can make a big difference. There are many great alternatives, but I have my favorites. Here are three brilliant growth stocks to buy now and hold for the long term.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Warren Buffett's mentor, Benjamin Graham, once wrote about an allegorical character he named "Mr. Market." Graham described Mr. Market as buying and selling at times based on wildly varying emotions. I think Mr. Market was alive and well (or perhaps, unwell) following Google parent Alphabet's (NASDAQ: GOOG) (NASDAQ: GOOGL) recent fourth-quarter update.
Alphabet reported strong numbers across the board. Yet the stock still declined sharply. Why? Investors focused on the company's plans to spend significantly more money on AI infrastructure in 2026.
The sell-off was -- like Graham's Mr. Market -- irrational, in my opinion. Alphabet is increasing its capital expenditures to capitalize on obvious growth opportunities. I think it would have been almost a dereliction of duty if management didn't boost capex significantly.
Pick any major technology that could shape the future (AI, quantum computing, robotics, self-driving cars, etc.). There's a good chance that Alphabet is already a leader in the field. I view this growth stock as a no-brainer to buy and hold.
You can pretty much apply everything I just said about Alphabet to Amazon (NASDAQ: AMZN). The main difference is that, unlike Alphabet, Amazon missed Wall Street's Q4 earnings estimate, albeit barely.
Yes, Amazon's 2026 capex guidance of roughly $200 billion is jaw-dropping. However, it's important to understand the context. Most of the investment will go to expanding AI infrastructure for Amazon Web Services (AWS). CEO Andy Jassy noted during the Q4 earnings call, "[W]e are monetizing capacity as fast as we can install it."
Selling the stock because of increased capex is tantamount to saying management doesn't know what it's doing. I believe Jassy and his team know exactly what they're doing. If any company can claim to understand demand and achieve exceptional returns on invested capital, it's Amazon.
Buying Amazon shares on pullbacks has always paid off handsomely over the long run. I'm confident that investing in this top AI stock will generate market-beating long-term returns this time around, too.
I'll step off my soapbox now and turn to one of the most promising biotech stocks on the market -- BeOne Medicines (NASDAQ: ONC). Unlike Alphabet and Amazon, BeOne is soaring so far in 2026. There's a good reason why. Actually, I think there are at least three good reasons why.
First, sales of BeOne's blood cancer therapy, Brukinsa, continue to skyrocket. BeOne expects to announce results from a Phase 3 study of the drug as a first-line treatment for mantle cell lymphoma (MCL) in the first half of this year.
Second, the company also hopes to win U.S. regulatory approval of sonrotoclax as a treatment for relapsed or refractory MCL in the first half of 2026. BeOne already secured Chinese regulatory approval for the drug earlier this year.
Third, yet another regulatory filing could be on the way in the second half of 2026. If the Phase 2 results for BGB-16673 in relapsed or refractory chronic lymphocytic leukemia are positive, BeOne plans to file for accelerated approval of the blood cancer therapy.
Are these potential upcoming catalysts reasons to buy and hold BeOne Medicines stock for the long term? Not on their own. However, they reflect a drugmaker that is continually innovating and winning. And that is a reason to buy and hold this stock.
Before you buy stock in Amazon, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $415,256!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,151,865!*
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 21, 2026.
Keith Speights has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, and BeOne Medicines Ag. The Motley Fool has a disclosure policy.